Login Register Cart 0
Generic placeholder image

Endocrine, Metabolic & Immune Disorders - Drug Targets

Editor-in-Chief

ISSN (Print): 1871-5303
ISSN (Online): 2212-3873

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Commentary

Conundrums in the Medical Treatment of Transgender Persons

Author(s): Charalampos Milionis, Eftychia Koukkou and Ioannis Ilias*

Volume 22, Issue 8, 2022

Published on: 29 April, 2022

Page: [795 - 797] Pages: 3

DOI: 10.2174/1871530322666220223161227

Next »
[1]
Jacobeit, J.W.; Gooren, L.J.; Schulte, H.M. Safety aspects of 36 months of administration of long-acting intramuscular testosterone undecanoate for treatment of female-to-male transgender individuals. Eur. J. Endocrinol., 2009, 161(5), 795-798.
[http://dx.doi.org/10.1530/EJE-09-0412] [PMID: 19749027]
[2]
Mueller, A.; Kiesewetter, F.; Binder, H.; Beckmann, M.W.; Dittrich, R. Long-term administration of testosterone undecanoate every 3 months for testosterone supplementation in female-to-male transsexuals. J. Clin. Endocrinol. Metab., 2007, 92(9), 3470-3475.
[http://dx.doi.org/10.1210/jc.2007-0746] [PMID: 17579193]
[3]
Deutsch, M.B. Overview of feminizing hormone therapy; UCSF Transgender Care: San Francisco, CA, 2016. Available from: https://transcare.ucsf.edu/guidelines/feminizing-hormone-therapy
[4]
Düsterberg, B.; Nishino, Y. Pharmacokinetic and pharmacological features of oestradiol valerate. Maturitas, 1982, 4(4), 315-324.
[http://dx.doi.org/10.1016/0378-5122(82)90064-0] [PMID: 7169965]
[5]
Sierra-Ramírez, J.A.; Lara-Ricalde, R.; Lujan, M.; Velázquez-Ramírez, N.; Godínez-Victoria, M.; Hernádez-Munguía, I.A.; Padilla, A.; Garza-Flores, J. Comparative pharmacokinetics and pharmacodynamics after subcutaneous and intramuscular administration of medroxyprogesterone acetate (25 mg) and estradiol cypionate (5 mg). Contraception, 2011, 84(6), 565-570.
[http://dx.doi.org/10.1016/j.contraception.2011.03.014] [PMID: 22078184]
[6]
Thurman, A.; Kimble, T.; Hall, P.; Schwartz, J.L.; Archer, D.F. Medroxyprogesterone acetate and estradiol cypionate injectable suspension (Cyclofem) monthly contraceptive injection: Steady-state pharmacokinetics. Contraception, 2013, 87(6), 738-743.
[http://dx.doi.org/10.1016/j.contraception.2012.11.010] [PMID: 23265980]
[7]
Mahase, E. HRT: Doctors demand talks with government to tackle “chaos” of shortages. BMJ, 2020, 368, m523.
[http://dx.doi.org/10.1136/bmj.m523] [PMID: 32029436]
[8]
Wise, J. Government imposes new restrictions on HRT exports to tackle shortages. BMJ, 2019, 367, l5838.
[http://dx.doi.org/10.1136/bmj.l5838] [PMID: 31582379]
[9]
Morris, E.; Currie, H.U.K. HRT shortages, how can this be good for anybody? Post Reprod. Health, 2020, 26(1), 3-4.
[http://dx.doi.org/10.1177/2053369120910693] [PMID: 32189554]
[10]
Farmer, Farmer K.C. Stress and strain on the U.S. drug supply: The intersection of shortages, globalization, counterfeit products, and throw in a global COVID-19 pandemic. J. Am. Pharm. Assoc . (2003) 2021, 61(1), e85-e6.
[11]
Cameron, E.E.; Bushell, M.A. Analysis of drug shortages across two countries during pre-pandemic and pandemic times. Res. Social Adm. Pharm., 2020.
[PMID: 33323334]
[12]
Vogler, S.; Fischer, S. How to address medicines shortages: Findings from a cross-sectional study of 24 countries. Health Policy, 2020, 124(12), 1287-1296.
[http://dx.doi.org/10.1016/j.healthpol.2020.09.001] [PMID: 33032846]
[13]
Safer, J.D.; Coleman, E.; Feldman, J.; Garofalo, R.; Hembree, W.; Radix, J.D.; Seveliusf, J. Barriers to health care for transgender individuals. Curr. Opin. Endocrinol. Diabetes Obes., 2016, 23(2), 168-171.
[http://dx.doi.org/10.1097/MED.0000000000000227] [PMID: 26910276]
[14]
Wylie, K.; Knudson, G.; Khan, S.I.; Bonierbale, M.; Watanyusakul, S.; Baral, S. Serving transgender people: Clinical care considerations and service delivery models in transgender health. Lancet, 2016, 388(10042), 401-411.
[http://dx.doi.org/10.1016/S0140-6736(16)00682-6] [PMID: 27323926]
[15]
Puckett, J.A.; Cleary, P.; Rossman, K.; Newcomb, M.E.; Mustanski, B. Barriers to gender-affirming care for transgender and gender nonconforming individuals. Sex. Res. Soc. Policy, 2018, 15(1), 48-59.
[http://dx.doi.org/10.1007/s13178-017-0295-8] [PMID: 29527241]
[16]
Vermeir, E.; Jackson, L.A.; Marshall, E.G. Barriers to primary and emergency healthcare for trans adults. Cult. Health Sex., 2018, 20(2), 232-246.
[http://dx.doi.org/10.1080/13691058.2017.1338757] [PMID: 28660795]
[17]
Bakko, M.; Kattari, S.K. Transgender-related insurance denials as barriers to transgender healthcare: Differences in experience by insurance type. J. Gen. Intern. Med., 2020, 35(6), 1693-1700.
[http://dx.doi.org/10.1007/s11606-020-05724-2] [PMID: 32128693]
[18]
Rodriguez, A.; Agardh, A.; Asamoah, B.O. Self-reported discrimination in health-care settings based on recognizability as transgender: A cross-sectional study among transgender U.S. citizens. Arch. Sex. Behav., 2018, 47(4), 973-985.
[http://dx.doi.org/10.1007/s10508-017-1028-z] [PMID: 28785919]
[19]
Kcomt, L.; Gorey, K.M.; Barrett, B.J.; McCabe, S.E. Healthcare avoidance due to anticipated discrimination among transgender people: A call to create trans-affirmative environments. SSM Popul. Health, 2020, 11100608
[http://dx.doi.org/10.1016/j.ssmph.2020.100608] [PMID: 32529022]
[20]
Stroumsa, D. The state of transgender health care: Policy, law, and medical frameworks. Am. J. Public Health, 2014, 104(3), e31-e38.
[http://dx.doi.org/10.2105/AJPH.2013.301789] [PMID: 24432926]
[21]
Radix, A. Primary care of transgender adults. In: Transgender Medicine - A Multidisciplinary Approach; Poretsky, L.; Hembree, W.C., Eds.; Humana Press/Springer Nature Switzerland AG: Cham, Switzerland, 2019, pp. 51-61.
[http://dx.doi.org/10.1007/978-3-030-05683-4_4]
[22]
Asscheman, H.; Giltay, E.J.; Megens, J.A.; de Ronde, W.P.; van Trotsenburg, M.A.; Gooren, L.J. A long-term follow-up study of mortality in transsexuals receiving treatment with cross-sex hormones. Eur. J. Endocrinol., 2011, 164(4), 635-642.
[http://dx.doi.org/10.1530/EJE-10-1038] [PMID: 21266549]
[23]
Streed, C.G., Jr; Harfouch, O.; Marvel, F.; Blumenthal, R.S.; Martin, S.S.; Mukherjee, M. Cardiovascular disease among transgender adults receiving hormone therapy: A narrative review. Ann. Intern. Med., 2017, 167(4), 256-267.
[http://dx.doi.org/10.7326/M17-0577] [PMID: 28738421]
[24]
Gooren, L.J.; Wierckx, K.; Giltay, E.J. Cardiovascular disease in transsexual persons treated with cross-sex hormones: Reversal of the traditional sex difference in cardiovascular disease pattern. Eur. J. Endocrinol., 2014, 170(6), 809-819.
[http://dx.doi.org/10.1530/EJE-14-0011] [PMID: 24616414]
[25]
Gooren, L.; Lips, P. Conjectures concerning cross-sex hormone treatment of aging transsexual persons. J. Sex. Med., 2014, 11(8), 2012-2019.
[http://dx.doi.org/10.1111/jsm.12563] [PMID: 24775178]
[26]
Gooren, L.J. T’Sjoen, G. Endocrine treatment of aging transgender people. Rev. Endocr. Metab. Disord., 2018, 19(3), 253-262.
[http://dx.doi.org/10.1007/s11154-018-9449-0] [PMID: 29922963]
[27]
Khosla, S.; Davidge-Pitts, C. Skeletal considerations in the medical treatment of transgender people. Lancet Diabetes Endocrinol., 2019, 7(12), 893-895.
[http://dx.doi.org/10.1016/S2213-8587(19)30353-5] [PMID: 31678063]

Rights & Permissions Print Cite
Article Metrics
15
1
© 2024 Bentham Science Publishers | Privacy Policy